Cover Image
市場調查報告書

疣的開發中產品分析

Warts - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200501
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
疣的開發中產品分析 Warts - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 85 Pages
簡介

疣是指人類乳突病毒(HPV)引發,小而無痛的部分皮膚腫瘤。疣存在許多種類,有出現在手上一般的疣,或是臉部、前額出現平板的疣,性器上產生的尖形濕疣,腳底出現的足部疣,手指甲·腳指甲下和周圍產生的指甲下·指甲周圍疣等。主要的症狀有傷口附近皮膚極黑或極白,前額、臉頰、手腕、腳有許多小而平滑的傷口、手、腳指甲下或周圍產生凹凸狀的腫瘤,腳底的橢圓狀傷口等。形狀皆是平坦而微微鼓起,伴隨有壓迫感,成為小小硬硬的傷口或腫塊。想要持續性除掉疣時有使用Podophyllin和水楊酸等醫藥品處方,但也有使用外科手術和冷凍(冷凍療法)、電燒方來除去。

本報告提供全球各國治療疣用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗各階段的產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

疣概要

治療藥的開發

  • 疣開發中產品:概要
  • 疣開發中產品:比較分析

各企業開發中的疣治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

疣治療藥:開發中的產品的一覽(各企業)

疣治療藥的開發企業

  • Helix BioPharma Corp.
  • CEL-SCI Corporation
  • NanoViricides, Inc.
  • 3M Drug Delivery Systems
  • G&E Herbal Biotechnology Co., Ltd.
  • Anaconda Pharma
  • Foamix Ltd.
  • BioMAS Ltd.
  • ViroStatics, srl
  • Cutanea Life Sciences
  • Burke Pharmaceuticals, LLC
  • Agilvax, Inc.
  • Nielsen Biosciences, Inc.

疣病:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 干擾素(interferon)·Alpha-2b (基因重組)
  • AS-101
  • SRT-100
  • AP-611074
  • Candida Albicans Antigen
  • (digoxin + furosemide)
  • 白血球白細胞介素
  • A-101
  • BURKE-201
  • AX-03
  • HerpeCide-I
  • imiquimod
  • 854-A
  • PP-210
  • Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts

疣治療藥:最新的藥物簡介

疣治療藥:暫停的計劃

疣治療藥:開發中止的產品

疣相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿(全8件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8294IDB

Summary

Global Markets Direct's, 'Warts - Pipeline Review, H2 2016', provides an overview of the Warts pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Warts
  • The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Warts therapeutics and enlists all their major and minor projects
  • The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Warts

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Warts
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Warts Overview
  • Therapeutics Development
    • Pipeline Products for Warts - Overview
  • Warts - Therapeutics under Development by Companies
  • Warts - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Warts - Products under Development by Companies
  • Warts - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Aclaris Therapeutics, Inc.
    • Agilvax, Inc.
    • Aviragen Therapeutics, Inc.
    • Biogenomics Limited
    • BioMAS Ltd.
    • Cytovation AS
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Laboratories Ojer Pharma S.L.
    • LEO Pharma A/S
    • Nielsen Biosciences, Inc.
    • Novan, Inc.
    • Novartis AG
    • Promius Pharma, LLC
    • RXi Pharmaceuticals Corporation
    • Tamir Biotechnology, Inc.
    • Verrica Pharmaceuticals Inc.
    • Zydus Cadila Healthcare Limited
  • Warts - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cervical cancer + genital warts) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (digoxin + furosemide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AX-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTA-074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Candida Albicans Antigen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CyPep-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFD-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diphencyprone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FIT-039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omiganan pentahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • povidone iodine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Warts - Dormant Projects
  • Warts - Discontinued Products
  • Warts - Product Development Milestones
    • Featured News & Press Releases
      • May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
      • Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
      • Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
      • Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Warts, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Warts - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Warts - Pipeline by Aclaris Therapeutics, Inc., H2 2016
  • Warts - Pipeline by Agilvax, Inc., H2 2016
  • Warts - Pipeline by Aviragen Therapeutics, Inc., H2 2016
  • Warts - Pipeline by Biogenomics Limited, H2 2016
  • Warts - Pipeline by BioMAS Ltd., H2 2016
  • Warts - Pipeline by Cytovation AS, H2 2016
  • Warts - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
  • Warts - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
  • Warts - Pipeline by LEO Pharma A/S, H2 2016
  • Warts - Pipeline by Nielsen Biosciences, Inc., H2 2016
  • Warts - Pipeline by Novan, Inc., H2 2016
  • Warts - Pipeline by Novartis AG, H2 2016
  • Warts - Pipeline by Promius Pharma, LLC, H2 2016
  • Warts - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Warts - Pipeline by Tamir Biotechnology, Inc., H2 2016
  • Warts - Pipeline by Verrica Pharmaceuticals Inc., H2 2016
  • Warts - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Warts - Dormant Projects, H2 2016
  • Warts - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Warts, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top